MiMedx Group’s EpiFixÂ® Receives American Podiatric Medical Association Seal of Approval
KENNESAW, Ga., Sept. 22, 2011 /PRNewswire/ — MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that the American Podiatric Medical Association (“APMA”) has granted its Seal of Approval for the Company’s EpiFixÂ® Amniotic Membrane Allograft.
For more than 35 years, APMA has been a reliable source of information on the quality and effectiveness of products that promote good foot health. Through its Seal of Approval, the APMA recognizes worthy products and provides a means by which manufacturers, providers and APMA can contribute to better foot health.
MiMedx Chairman and CEO, Parker H. “Pete” Petit, stated, “We are extremely pleased to have our wound care offering, EpiFixÂ®, recognized by APMA. APMA is renowned for its work in providing information for podiatric physicians, their patients and the general public to ensure that they make the best possible decisions regarding foot health. The Seal of Approval is granted by APMA’s Board of Trustees following the successful completion of an extensive review process in which the foot care product is scientifically evaluated. We are proud that EpiFixÂ® has met APMA’s requirements and received this recognition.”
“A major goal of APMA is to raise awareness by identifying products of exceptional quality that are manufactured with the consumer’s comfort and safety in mind,” said Dr. Matthew Garoufalis, D.P.M., Vice President of American Podiatric Medical Association. “The APMA Seal of Approval is only granted when evidence of safety and effectiveness of a product has been established by an appropriate recognized laboratory and/or clinical investigation applicable to the therapeutic (medical) agents under our consideration.”
“We place a tremendous emphasis on the quality, safety and the efficacy of our offerings,” added Bill Taylor, MiMedx President and COO. “It is always gratifying when our products and tissues are recognized for excellence by independent authorities.”
MiMedxÂ® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. “Innovations in Regenerative Biomaterials” is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix(TM) and CollaFix(TM), and our tissue technologies, AmnioFixÂ® and EpiFixÂ®. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary PurionÂ® process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant. Surgical Biologics is the leading supplier of amniotic tissue, having supplied over 35,000 implants to date to distributors and OEMs for application in the Ophthalmic, Orthopedics, Spine, Wound Care and Dental sectors of healthcare.
Founded in 1912, the American Podiatric Medical Association (APMA) is the nation’s leading and recognized professional organization for doctors of podiatric medicine (DPMs). DPMs are podiatric physicians and surgeons, also known as podiatrists, qualified by their education, training and experience to diagnose and treat conditions affecting the foot, ankle, and structures of the leg. The medical education and training of a DPM includes four years of undergraduate education, four years of graduate education at an accredited podiatric medical college, and two or three years of hospital residency training. APMA has 53 state component locations across the United States and its territories, with a membership of close to 12,000 podiatrists. All practicing APMA members are licensed by the state in which they practice podiatric medicine. For more information, visit www.apma.org.
SOURCE MiMedx Group, Inc.